A phase i study of temsirolimus and metformin in advanced solid tumours

Investigational New Drugs

Volumn 30, Issue 2, 2012, Pages 647-652

  MacKenzie, Mary J ^a   Ernst, Scott ^a   Johnson, Craig ^a   Winquist, Eric ^a  

^a LONDON HEALTH SCIENCES CENTRE   (Canada)

Author keywords

Advanced solid tumours; AMPK; Metformin; mTOR; Temsirolimus

Indexed keywords

CISPLATIN; DOCETAXEL; METFORMIN; TEMSIROLIMUS; ZALUTUMUMAB; ANTINEOPLASTIC AGENT; DRUG DERIVATIVE; MTOR PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; CLINICAL ARTICLE; CONSTIPATION; COUGHING; DIARRHEA; DISEASE ACTIVITY; DISEASE DURATION; DRUG ERUPTION; DRUG MEGADOSE; DRUG RESPONSE; DYSPHAGIA; DYSPNEA; EDEMA; EPISTAXIS; FATIGUE; FEMALE; FEVER; HEAD AND NECK CANCER; HEADACHE; HUMAN; HYPERGLYCEMIA; HYPERTRIGLYCERIDEMIA; INSOMNIA; INTESTINE OBSTRUCTION; LEG EDEMA; LEUKOPENIA; LUNG INFILTRATE; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; MYALGIA; NAUSEA; NEUTROPENIA; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; SENSORY NEUROPATHY; SOLID TUMOR; STOMATITIS; TASTE DISORDER; THROMBOCYTOPENIA; VOMITING; CANADA; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG ANTAGONISM; ENZYMOLOGY; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; MIDDLE AGED; NEOPLASM; ORAL DRUG ADMINISTRATION; PATHOLOGY; PILOT STUDY; TIME; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MAXIMUM TOLERATED DOSE; METFORMIN; MIDDLE AGED; NEOPLASMS; ONTARIO; PILOT PROJECTS; PROTEIN KINASE INHIBITORS; SIROLIMUS; TIME FACTORS; TOR SERINE-THREONINE KINASES; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84862248731     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-010-9570-8     Document Type: Article

References (21)

1. Sabatini DM (2006) mTor and cancer: insights into a complex relationship. Nat Rev Cancer 6:729-734
2. Shor B, Zhang WG, Toral-Barza L, Lucas J, Abraham RT, Gibbons JJ, Yu K (2008) A new pharmacologic action of CCI-779 involves FKBP 12-independent inhibition of mTOR kinase activity and profound repression of global protein synthesis. Cancer Res 68:2934-2943
3. Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O'Toole T, Lustgarten S, Moore L, Motzer RJ, Global ARCC Trial (2007) Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 356:2271-2281
4. Hess G, Herbrecht R, Romaguera J, Verhoef G, Crump M, Gisselbrecht C, Laurell A, Offner F, Strahs A, Berkenblit A, Hanushevsky O, Clancy J, Hewes B, Moore L, Coiffier B (2009) Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27:3822-3829
5. Oza AM, Elit L, Biagi J, Chapman W, Tsao M, Hedley D, Hansen C, Dancey J, Eisenhauer E (2006) Molecular correlates associated with a phase II study of temsirolimus (CCI-779) in patients with metastatic or recurrent endometrial cancer - NCIC IND 160. Proc Am Sci Clin Oncol Part I 24(18S), abstract 3003
6. Okuno SH, Mahoney MR, Bailey HH, Adkins DR, Maples WJ, Ettinger D, Fitch TR, Bot BM, Erlichman CE (2006) A multicenter phase 2 consortium (P2C) study of the mTOR inhibitor CCI-779 in advanced soft tissue sarcomas (STS). Proc Am Sci Clin Oncol Part I 24(18S), abstract 9504
7. Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, Le L, Oza A, Nicklee T, Ho J, Birle D, Pond GR, Arboine D, Dancey J, Aviel-Ronen S, Tsao MS, Hedley D, Siu LL (2006) A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95:1148-1154
8. Ml R, Schadt EE (2007) Pharmacogenetics of metformin response: a step in the path toward personalized medicine. J Clin Invest 117:1126-1129
9. Bowker SL, Veuglers P, Majumdar SR, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diab Care 29:254-258
10. Evans SM, Donnelly LA, Emslie-Smith AM, Alessi DR, Morris AD (2005) Metformin and reduced risk of cancer in diabetic patients. BMJ 330:1304-1305
11. Zakihani M, Dowling R, Fantus IG, Sonenberg N, Pollak M (2006) Metformin is an AMP-kinase dependent growth inhibitor for breast cancer cells. Cancer Res 66:10269-10273
12. Alimova IN, Liu B, Edgerton S, Dillon T, Thor A (2007) Metformin, an anti-diabetic agent inhibits breast cancer cell growth in vitro. AACR Annual Meeting 2007 Abstract 3277
13. Buzzai M, Jones RJ, Lum ARK, JJ DeBerardinis RJ, Zhao F, Viollet B, Thompson CB (2007) Systemic treatment with the antidiabetic drug metformin selectively impairs p53 deficient tumor cell growth. Cancer Res 67:6745-6752
14. Zakikhani M, Pollack M (2007) Adiponectin and metformin inhibit prostate and colon cancer cell proliferation via AMP kinase dependent mechanism. AACR Annual meeting 2007 Abstract 4467
15. Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, Hsu L, Hung MC, Hortobagyi GN, Gonzalez-Angulo AM (2007) Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol 27:3297-3302
16. Sengupta TK, Leclerc GM, Hsieh-Kinser TT, Leclerc GJ, Singh I, Barredo JC (2007) Cytotoxic effect of 5-aminoimidazole-4-carboxamide-1-beta-D- ribofuranoside (AICAR) on childhood acute lymphoblastic leukemia cells: implication for targeted therapy. Mol Cancer 6:46
17. Elizalde VS, Russillo M, Scaltriti M, Rodriguez O, Guzman M, Di Cosimo S, Baselga J (2010) Dual-targeting of AMPK and PI3K/mTOR in a panel of breast cancer cell lines. Proc Am Assoc Cancer Res Annual Gen Meeting abstract 4477
18. Zakikhani M, Blouin MJ, Piura E, Pollack MN (2010) Metformin and rapamycin have distinct effects on the AKT pathway and proliferation in breast cancer cells. Breast Cancer Res Treat 123:271-279
19. Armstrong AJ, George DJ, Halabi S (2010) Evaluation of serum lactate dehydrogenase (LDH) as a predictive biomarker for mTOR inhibition in patients with metastatic renal cell carcinoma (RCC). Proc Am Sco Clin Oncol Genitourinary Symposium 2010, abstract 324
20. Woodard J, Platanias LC (2010) AMP-activated kinase (AMPK)-generated signals in malignant melanoma cell growth and survival. Biochem Biophys Res Commun 398(1):135-139
21. Jalving M, Gietema JA, Lefrandt JD, de Jong S, Reyners AKL, Gans ROB, de Vries EGE (2010) Metformin: taking the candy away for cancer? Eur J Cancer 46:2369-2380